Ragweed Mix Allergy Shots: What's in the Vial and Why
Most US ragweed allergy shots are a clinical mix — typically FDA-standardized Ambrosia artemisiifolia (short ragweed) as the Amb a 1-quantified backbone plus non-standardized A. trifida (giant ragweed) — because 63% of US allergists treat 6 or more allergens per vial and most ragweed-allergic patients are polysensitized. The mix is supported indirectly by Creticos 2006 NEJM via Ambrosia genus cross-reactivity, though no head-to-head RCT compares it to single-species short-ragweed SCIT.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Ragweed Mixis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Ragweed Mix Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to ragweed mix — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of ragweed mix allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of ragweed mix immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of ragweed mix extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for ragweed mix allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing ragweed mix extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription ragweed mix immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat ragweed mix allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Ragweed Mix?
The biology, taxonomy, and clinical fingerprint of Ragweed Mix — the foundation of how SCIT targets it.
Ragweed-mix SCIT vials typically contain FDA-standardized short-ragweed extract as the Amb a 1-quantified backbone plus non-standardized giant-ragweed extract; the relative proportions vary by regional practice and patient sensitization pattern.
- Scientific name
- Multi-species (Ambrosia artemisiifolia + A. trifida ± A. psilostachya)
- Family
- AsteraceaeSunflower family
- Type
- Clinical multi-species weed pollen mixture
- Native to
- North America (combined range of included Ambrosia species)
- Allergen proteins
- Amb a 1 (major) — pectate lyase from A. artemisiifolia, dose-quantified backboneAmb t 5 — pectate lyase from A. trifida (>90% identity with Amb a 1)Amb p 5 — pectate lyase from A. psilostachya (when included)Amb a 8 — profilin (ragweed-melon-banana syndrome mediator)Amb a 11 — cysteine protease (~65% sensitization, asthma association)
- Particle size
- 16–27 µm (varies by species)
- Avoidance difficulty
- Nearly impossible
How Ragweed Mix Allergy Presents
Symptoms by body system — useful for distinguishing Ragweed Mix sensitivity from overlapping allergies and infections.
Respiratory
- Combined-species rhinorrhea beginning July in giant-ragweed-exposed Midwest patients, August in predominantly short-ragweed eastern patients
- Nasal congestion and post-nasal drip from sustained multi-species Ambrosia exposure
- Sneezing from additive pollen load when A. artemisiifolia and A. trifida seasons overlap (August–September in Midwest)
- Asthma exacerbations in polysensitized patients who also have sagebrush or grass sensitization
- Extended seasonal rhinitis burden across the combined July–November window in patients whose mix vial covers multiple species
Ocular
- Bilateral conjunctivitis with itching, tearing, and redness across the combined Ambrosia season
- Eyelid edema during peak August–September counts when both A. artemisiifolia and A. trifida are releasing simultaneously
- Photophobia in patients with additional grass or tree co-sensitization who experience a prolonged multispecies season
- Allergic shiners from sustained seasonal inflammation
Skin
- Contact dermatitis from direct plant exposure across multiple Ambrosia species habitats
- Perioral itching or tingling after eating cantaloupe, honeydew, watermelon, banana, or cucumber
- Urticaria in highly sensitized patients during peak combined-species pollen events
- Atopic dermatitis exacerbations coinciding with the combined Ambrosia season
Systemic
- Fatigue and cognitive impairment from sustained multi-species Ambrosia exposure across an extended season
- Oral allergy syndrome with melon, banana, cucumber, chamomile, and sunflower seeds via Amb a 8 profilin
- Sleep disruption from the combined polysensitization histamine burden
- Reduced quality of life across the full July–November window when multiple Ambrosia species are in play
In my practice, the ragweed-mix is the default — most patients reacting in ragweed season respond to both short and giant ragweed without knowing it. The key discipline is preserving the Amb a 1 backbone dose when adding the giant-ragweed component. Dilute that dose below 6 micrograms and we leave the efficacy range Creticos established.
When & Where Ragweed Mix Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late July through mid-October for combined Ambrosia exposure in eastern and Midwest US· ~12–16 weeks when both A. artemisiifolia (Aug–Nov) and A. trifida (Jul–Oct) seasons are combined
US Exposure Map
19 high-intensity statesExposure intensity by state (text version)
- ME:
- Moderate
- VT:
- Moderate
- NH:
- Moderate
- WA:
- Low
- MT:
- Low
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- Moderate
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Moderate
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- Moderate
- RI:
- Moderate
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- High
- MO:
- High
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Moderate
- TN:
- High
- NC:
- Moderate
- SC:
- Moderate
- OK:
- Moderate
- LA:
- Moderate
- MS:
- Moderate
- AL:
- Moderate
- GA:
- Moderate
- TX:
- Moderate
- FL:
- Moderate
- AK:
- Low
- HI:
- Low
What Ragweed Mix Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
The ragweed-mix vial contains allergens from two or three Ambrosia species that share near-complete Group 1 pectate-lyase cross-reactivity, making the FDA-standardized short-ragweed backbone the dose-controlling agent; additional cross-reactivity extends to mugwort and pollen-food syndrome foods through shared profilin (Amb a 8) and other pan-allergens.
Primary mix component; FDA-standardized A. artemisiifolia provides the Amb a 1 dose backbone
Sometimes included in eastern mixes; Amb p 5 / Amb a 1 strong cross-reactivity
Parallel Plains/Western regional formulation targeting A. psilostachya and A. acanthicarpa
Amb a 4 / Art v 1 Asteraceae bridge; co-sensitization common in late-summer broad Asteraceae exposure
Amb a 8 profilin cross-reactivity mediating ragweed-melon-banana syndrome
Cucurbitaceae profilin cross-reactivity
Profilin cross-reaction; worsens during combined Ambrosia season
Ragweed-Melon-Banana Syndrome (Multi-species Mix)
All Ambrosia species in a ragweed-mix vial carry profilin allergens cross-reactive with cucurbit and Musaceae foods, meaning ragweed-mix-sensitized patients carry the same oral allergy syndrome risk as single-species ragweed patients — with a potentially longer season of symptom vulnerability when multiple species are in the mix.
Is SCIT Right for Your Ragweed Mix Allergy?
Answer five questions to understand your SCIT candidacy profile for polysensitized ragweed allergy — the patient profile ragweed-mix SCIT is designed for.
How severe are your combined ragweed-season symptoms across the July–October window?
The Ragweed Mix SCIT Protocol
Ragweed-mix SCIT preserves the FDA-standardized Ambrosia artemisiifolia extract as the Amb a 1-quantified backbone — targeting 6–24 µg Amb a 1 per maintenance injection per AAAAI Practice Parameters and Creticos 2006 NEJM dosing — while adding non-standardized A. trifida (and sometimes A. psilostachya) components proportioned to maintain the backbone dose within the efficacy range.
Progressive dose escalation from dilute starting concentrations toward the maintenance target, preserving the Amb a 1 backbone proportion. Midwest allergists targeting both A. artemisiifolia and A. trifida seasons often schedule build-up from October through June so that maintenance is reached before the July A. trifida onset. The mandatory 30-minute post-injection observation period applies at every build-up visit. Dose adjustments are made if large local or systemic reactions occur with the combined vial.
Ongoing maintenance at the Amb a 1 target dose (6–24 µg), which is the dosing anchor regardless of how many Ambrosia species are in the vial. Seasonal dose reductions during the August–October peak window are standard. Clinical benefit — measured as significantly reduced combined symptom-medication scores — typically accumulates across multiple complete fall seasons.
Patients completing the full course typically experience sustained immune tolerance persisting years beyond treatment. The decision to stop is individualized based on symptom history and whether component testing shows reduction in specific Ambrosia IgE over the treatment course.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Ragweed Mix SCIT
Ragweed-mix SCIT efficacy is supported indirectly by the short-ragweed evidence base — most notably Creticos 2006 NEJM — via the near-complete Ambrosia genus cross-reactivity; no head-to-head RCT comparing ragweed-mix against single-species short-ragweed SCIT has been published.
- Nasal symptom reduction (short-ragweed backbone benchmark)85%
- Pooled ragweed SCIT symptom improvement (meta-analysis, including multi-species extracts)73%Frew AJ et al. 2008, Allergy 63:1107 — SMD −0.73 for ragweed SCIT
- Ambrosia cross-reactivity supporting mix coverage90%Wopfner N et al. 2005, Int Arch Allergy Immunol 138:337 — Group 1 pectate-lyase conservation
- Cochrane NNT for seasonal allergic rhinitis injection immunotherapy67%Calderon MA et al. 2007, Cochrane Database Syst Rev CD001936 — NNT ~3 (67% benefit rate above placebo)
No published RCT directly compares ragweed-mix SCIT against single-species short-ragweed SCIT for symptom outcomes; the clinical rationale for the mix approach rests on the well-characterized Ambrosia genus cross-reactivity (Wopfner 2005) and the Amb a 1 dose-preservation principle endorsed by AAAAI Practice Parameters. Patients should be informed that the mix's efficacy is extrapolated from the Creticos 2006 NEJM single-species benchmark rather than directly demonstrated in a head-to-head comparison.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Ragweed Mix SCIT Side Effects
Ragweed-mix SCIT side effects follow standard inhalant SCIT parameters; because the vial contains multiple extract components, any dose adjustment triggered by a reaction applies to the entire combined preparation.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site redness and swelling Expected with multi-component vials; ice and antihistamine management | Rate 30–50% | Mild |
Localized itching at injection site | Rate 20–40% | Mild |
Large local reaction (>5 cm) With multi-component vials, the component responsible is often unclear — the full combined dose is adjusted | Rate 3–10% | Moderate |
Delayed soreness (8–24 hours) | Rate 10–20% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Nasal or ocular flare | Rate 0.5–1% of injections | Mild |
Generalized urticaria | Rate 0.1–0.3% of injections | Moderate |
Mild asthma exacerbation Spirometry screening before injection during peak August–October season; higher risk with combined vials if asthma is not well controlled | Rate <0.1% of injections | Moderate |
Anaphylaxis Mandatory 30-minute post-injection observation; epinephrine auto-injector prescribed | Rate <0.01% of injections | Severe |
The mandatory 30-minute post-injection observation period is the primary safety backstop for all SCIT. Multi-allergen vials containing ragweed mix alongside other weed or grass extracts should be designed to avoid diluting the Amb a 1 backbone below therapeutic thresholds while keeping total injection volume within safe limits — typically ≤0.5 mL per injection site.
SCIT vs Alternatives for Ragweed Mix
Polysensitized ragweed patients considering a ragweed-mix approach have four main options: multi-species SCIT (the most durable), at-home SLIT drops covering multiple Ambrosia species, avoidance (limited), or long-term antihistamines plus nasal corticosteroids.
| Criterion | At-Home SCIT (Curex)Best | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | ~85% via Amb a 1 backbone benchmark (Creticos 2006 NEJM); mix efficacy extrapolated via cross-reactivity | Ragwitek (short ragweed tablet) covers mix via cross-reactivity; ~27% TCS reduction; custom drops extend to multi-species | Very limited — Ambrosia pollen travels 300–400 miles across combined species range | Good short-term control; breakthrough common across the extended combined Ambrosia season |
| 5-yr cost | $3,500–$12,000 over 5 yrs | $1,500–$5,000 over 3 yrs | Low | $500–$3,000 over 5 yrs |
| Duration | 3–5 years | 3 years tablets or ongoing drops | Ongoing every season | Annual, indefinitely |
| Convenience | Self-administered weekly at home with Curex during build-up, then ongoing maintenance — no clinic visits | Daily sublingual dose at home — key advantage for multi-species coverage without clinic visits | HEPA filtration; indoor refuge during peak | Daily or as-needed |
| Safety | Rare anaphylaxis (onset within ~30 min); Curex confirms a prescribed epinephrine auto-injector on hand and supervises the first injection from each new vial or concentration live in the Virtual Shot Room | Local oral irritation; anaphylaxis very rare | No clinical risk | Antihistamine sedation possible |
| Lasting effect | Years of remission post-completion | Moderate lasting effect | No immune modification | No lasting effect |
At-Home SCIT (Curex)Best
SLIT
Avoidance
Medications
Multi-species ragweed SCIT delivers the most durable outcome for polysensitized patients, preserving the Amb a 1 efficacy benchmark while adding giant-ragweed coverage for the Midwest early season. Curex delivers that same multi-species ragweed immunotherapy as a weekly shot you give yourself at home, with pricing confirmed in a current program quote — a personalized serum sterile-compounded to USP <797>, the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, with a prescribed epinephrine auto-injector confirmed on hand. It removes the weekly clinic trips of traditional build-up for eligible patients.
What Ragweed Mix SCIT Actually Costs
Ragweed-mix SCIT is billed under the same standard allergy immunotherapy codes as single-species ragweed SCIT; because the backbone is FDA-standardized, insurance coverage follows the same pathway. Multi-allergen vials may be billed separately if allergens are drawn from different manufacturers; confirm prior-authorization requirements with your insurer. For polysensitized patients who prefer at-home treatment, Curex delivers a personalized multi-species ragweed immunotherapy as a self-administered weekly shot with pricing confirmed in a current program quote; confirm quote inclusions (serum, supplies, and care team, HSA/FSA eligible) — matched to your individual IgE results, with no per-visit copays.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your ragweed mix allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Ragweed Mix SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
A standard US ragweed-mix vial contains FDA-standardized short-ragweed extract (Ambrosia artemisiifolia, labeled in Amb a 1 µg/mL — typically 300 µg/mL stock) as the dose-controlling backbone, plus one or more non-standardized Ambrosia species extracts — most commonly A. trifida (giant ragweed) and sometimes A. psilostachya (western ragweed). The short-ragweed component is the only standardized extract and the clinically proven dose anchor; AAAAI Practice Parameters and Creticos 2006 NEJM both target 6–24 µg Amb a 1 per maintenance injection. The non-standardized components are proportioned by your allergist to provide additional species coverage without diluting the Amb a 1 dose below the efficacy threshold. Composition varies by manufacturer and regional practice.
The honest clinical answer is that no head-to-head RCT has directly compared ragweed-mix SCIT against single-species short-ragweed SCIT for symptom outcomes. The rationale for equivalent efficacy rests on two well-established findings: the Ambrosia genus cross-reactivity data showing >90% Group 1 pectate-lyase sequence identity across species (Wopfner 2005), and the AAAAI Practice Parameter guidance that dose-preservation of the Amb a 1 backbone at 6–24 µg per maintenance injection is the key efficacy variable — regardless of which other Ambrosia species are in the vial. Provided the short-ragweed backbone dose is maintained, the mix should deliver efficacy equivalent to the Creticos 2006 NEJM benchmark. The clinical risk of a mix approach is inadvertently diluting the Amb a 1 dose by adding too many secondary extracts; this is why allergists carefully calculate vial composition before compounding.
Your ragweed-mix vial label should show the short-ragweed (Ambrosia artemisiifolia) component in Amb a 1 µg/mL — this is the dose you should confirm with your allergist. Common stock concentrations are 300 µg/mL; the maintenance vial is typically diluted to deliver 6–24 µg Amb a 1 per 0.5 mL injection. Giant ragweed (A. trifida) and other secondary components are usually labeled in weight-to-volume (W/V, such as 1:10 w/v) or protein nitrogen units (PNU/mL) — these units reflect the non-standardized extract concentration and cannot be directly compared to the Amb a 1 µg designation of the short-ragweed backbone. If your vial label only shows W/V or PNU for all components without an Amb a 1 µg designation for the short-ragweed fraction, ask your allergist to confirm that the standardized backbone dose is within the AAAAI-recommended range.
Ragweed-mix SCIT targets Ambrosia species via the Amb a 1 family pectate-lyase; mugwort (Artemisia vulgaris) carries a different major allergen — Art v 1, a defensin-like protein — that is not covered by Ambrosia SCIT. The biochemical bridge between ragweed and mugwort exists at the Amb a 4 / Art v 1 level (approximately 69% sequence identity), but this cross-reactivity is partial and not sufficient for clinical cross-protection through immunotherapy. Patients with confirmed mugwort sensitization alongside ragweed sensitization typically require a separate Artemisia extract vial in their SCIT regimen — either a single-species mugwort extract or a sage-mix formulation covering Artemisia species. Your allergist can identify whether your fall Asteraceae allergy involves both the Ambrosia (ragweed) and Artemisia (mugwort/sage) families and compound a complete vial set accordingly.
Switching from a ragweed-mix to single-species short-ragweed SCIT is clinically reasonable if component-resolved diagnostic testing confirms that your IgE sensitization is actually dominated by A. artemisiifolia Amb a 1 — meaning you are functionally mono-sensitized — and the secondary Ambrosia species in your current vial are adding volume without adding meaningful clinical benefit. This simplification can improve dose precision: a vial containing only standardized short-ragweed extract is easier to dose-target at the 6–24 µg Amb a 1 maintenance level without the compounding variability introduced by non-standardized secondary components. The transition typically involves a brief dose step-down on switching to a new vial, per standard SCIT lapse protocols. Discuss the switch with your allergist, who can review your recent component testing and reaction history to determine if the simplification is appropriate.
Ragweed-mix SCIT targets the Ambrosia IgE response broadly, and because ragweed-melon-banana syndrome is driven by pollen sensitization (primarily Amb a 8 profilin cross-reacting with cucurbit and Musaceae foods), treating the pollen allergy through SCIT may reduce oral allergy syndrome cross-reactions over time. Clinical experience from seasonal pollen SCIT suggests that patients who complete 2–3 years of ragweed SCIT often report improved tolerance of raw cantaloupe, watermelon, banana, and cucumber, particularly outside peak ragweed season. These improvements are not guaranteed and individual results vary. OAS-associated foods are typically heat-labile (cooking eliminates reactions), so cooked versions of melon and cucurbit foods can usually be eaten year-round regardless of SCIT status. Inform your allergist of any food reactions before starting injections — anaphylaxis from chamomile tea or echinacea in ragweed-sensitized patients has been documented. As for the injections themselves, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
The ragweed-mix approach is the US clinical norm because most ragweed-allergic patients are polysensitized — they react to more than one Ambrosia species on skin testing, even though the dominant allergen driving the reaction (Amb a 1-family pectate lyase) is shared across species. Skoner et al. (2010, JACI) found that 63% of US allergists use 6 or more allergens per vial, reflecting the reality that patients' exposures don't fit single-species categories. A patient in the Midwest who tests positive to both short ragweed and giant ragweed benefits from a mix vial that covers the August–October short-ragweed peak and the earlier July giant-ragweed season simultaneously. Your allergist's mix decision is based on your skin-test or IgE panel results and your geographic exposure pattern — if both species are positive, a mix makes clinical sense even though the short-ragweed backbone provides most of the cross-coverage.
Insurance billing for ragweed-mix SCIT follows the same CPT code framework as single-species ragweed SCIT — 95115 (single injection), 95117 (multiple injections at the same visit), and 95165 (extract preparation per dose unit). The mix composition does not change the billing codes, though the extract preparation code (95165) may be billed with a higher unit count if multiple separately prepared extracts are combined. Some insurers require prior authorization and documentation of the sensitization pattern justifying the multi-species formulation. As with any SCIT, coverage depends on your plan's allergy benefits, deductible, and whether the prescribing allergist is in-network. Calling your insurer ahead of treatment to confirm that multi-allergen SCIT is covered under your plan's allergy benefit is always worthwhile.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.